Evidence map›Paper›PMID 38730694›Full record

ArticleCancers2024

Quantitative Assessment of Tumor Contact with Neurogenic Zones and Its Effects on Survival: Insights beyond Traditional Predictors.

Kirsten Jung, Johanna Kempter, Georg Prokop, Tim Herrmann, Michael Griessmair, Su-Hwan Kim, Claire Delbridge, Bernhard Meyer, Denise Bernhardt, Stephanie E Combs and 4 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kirsten JungDepartment of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.
Johanna KempterDepartment of Neurology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.ORCID 0000-0002-2599-588X
Georg ProkopDepartment of Neurology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.
Tim HerrmannDepartment of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.
Michael GriessmairDepartment of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.ORCID 0009-0007-3518-0792
Su-Hwan KimDepartment of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.ORCID 0000-0002-5383-2041
Claire DelbridgeDepartment of Pathology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.ORCID 0000-0003-4339-6917
Bernhard MeyerDepartment of Neurosurgery, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.ORCID 0000-0001-6486-7955
Denise BernhardtDepartment of Radiation Oncology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.
Stephanie E CombsDepartment of Radiation Oncology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.
Claus ZimmerDepartment of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.
Benedikt WiestlerDepartment of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.ORCID 0000-0002-2963-7772
Friederike Schmidt-GrafDepartment of Neurology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.
Marie-Christin MetzDepartment of Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 München, Germany.ORCID 0000-0002-1459-5741

Funding

Generalizable quantitative imaging and machine learning signatures in glioblastoma, for precision diagnostics and personalized treatment: the ReSPOND consortiumR01CA269948 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Christos Davatzikos · 2022 to 2026
$3.2M
NCI NIH HHS R01 CA269948
6 · The paper itself

Abstract

So far, the cellular origin of glioblastoma (GBM) needs to be determined, with prevalent theories suggesting emergence from transformed endogenous stem cells. Adult neurogenesis primarily occurs in two brain regions: the subventricular zone (SVZ) and the subgranular zone (SGZ) of the hippocampal dentate gyrus. Whether the proximity of GBM to these neurogenic niches affects patient outcome remains uncertain. Previous studies often rely on subjective assessments, limiting the reliability of those results. In this study, we assessed the impact of GBM's relationship with the cortex, SVZ and SGZ on clinical variables using fully automated segmentation methods. In 177 glioblastoma patients, we calculated optimal cutpoints of minimal distances to the SVZ and SGZ to distinguish poor from favorable survival. The impact of tumor contact with neurogenic zones on clinical parameters, such as overall survival, multifocality, MGMT promotor methylation, Ki-67 and KPS score was also examined by multivariable regression analysis, chi-square test and Mann-Whitney-U. The analysis confirmed shorter survival in tumors contacting the SVZ with an optimal cutpoint of 14 mm distance to the SVZ, separating poor from more favorable survival. In contrast, tumor contact with the SGZ did not negatively affect survival. We did not find significant correlations with multifocality or MGMT promotor methylation in tumors contacting the SVZ, as previous studies discussed. These findings suggest that the spatial relationship between GBM and neurogenic niches needs to be assessed differently. Objective measurements disprove prior assumptions, warranting further research on this topic.

Indexed as

computationalglioblastomaquantitativeSGZsurvivalSVZ

Identifiers

PMID38730694
PMCPMC11083354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.